unistrain prrs
laboratorios hipra, s.a., avda. la selva, 135, 17170 amer (girona), Španjolska - živi atenuirani virus reproduktivnog i respiratornog sindroma svinja (engl. porcine reproductive and respiratory sydrome virus, prrsv), soj vp-046 bis - liofilizat i otapalo za suspenziju za injekciju - živo virusno cjepivo, virusno cjepivo protiv reproduktivnog i respiratornog sindroma svinja (engl. porcine reproductive and respiratory syndrome, prrs) - svinja
stallerpoint 10x10 igala
medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -
regumate porcine
intervet international b.v., podružnica u republici hrvatskoj, ivana lučića 2a, 10000 zagreb, hrvatska - altrenogest - peroralna otopina - svinja
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
ingelvac prrsflex eu
boehringer ingelheim vetmedica gmbh, binger straße 173, 55216 ingelheim am rhein, njemačka - atenuirani virus reproduktivnog i respiratornog sindroma svinja (engl. porcine reproductive and respiratory syndrome virus, prrsv), soj 94881 (genotip 1) - liofilizat i otapalo za suspenziju za injekciju, za svinje - svinja (svinje od 17. dana života do kraja tova)
reprocyc prrs eu
boehringer ingelheim vetmedica gmbh, binger straβe 173, 55216 ingelheim am rhein, njemačka - atenuirani virus reproduktivnog i respiratornog sindroma svinja (engl. porcine reproductive and respiratory syndrome virus, prrsv), soj 94881 (genotip 1) - liofilizat i otapalo za suspenziju za injekciju - svinja (rasplodne nazimice i krmače)
suvaxyn circo+mh rtu
zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - Инактивированные virusnih i инактивированные bakterijska cjepiva - svinje - za aktivne imunizacije svinja s 3 tjedna starosti protiv svinjske цирковирус tipa 2 (pcv2) za smanjenje količine virusa u krvi i лимфоидных tkiva i fekalne prolijevanja, uzrokovane infekcijom s ЦВС2. za aktivnu imunizaciju svinja u dobi od 3 tjedna protiv mycoplasma hyopneumoniae za smanjenje plućnih lezija uzrokovanih infekcijom s m. hyopneumoniae.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunološke za suidae - svinja (za tov) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresivi - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
invanz
merck sharp & dohme b.v. - ertapenem natrij - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - antibakterijski lijekovi za sistemsku primjenu, - treatmenttreatment od sljedećih infekcija kada su uzrokovane bakterijama poznato ili s velikom vjerojatnošću će podložno эртапенем i kada парентеральной terapije potrebno je:интраабдоминальные infekcije;внебольничная upala pluća;akutne ginekološki bolesti;dijabetes i stopala infekcije kože i mekih tkiva. preventioninvanz navodi u odraslih za prevenciju kirurške infekcije nakon planske колоректальной kirurgija. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.